Name
BEMP
Alternate names
None
Primary Site
None
Histology
None
Radiation
None
Remarks
None
Drugs for BEMP
Name
Alternate Names
Ametycine
Mito-Medac
Mitocin
Mitocin-C
MitoExtra
Mitomycin-C
Mitomycin-X
Mutamycin
Mutamycine
Abbreviations
MITC
Mito
MITO-C
MMC
MTC
Category
Chemotherapy
Subcategory
Alkylating agent
Antibiotic
NSC Number
26980
026980
Primary Site
Breast
Cervical cancer
Gastric cancer
Non-small cell lung cancer (NSCLC)
Pancreatic cancer
Superficial bladder cancer
Histology
None
Remarks
Coding
This drug should be coded
Name
Alternate Names
Cis-Platin
Cis-Platinum II#
Cisplatino (Spanish)
Cisplatinum
Cisplatyl
Neoplatin
Peyrone's chloride
Platinex
Platinol
Platinol-AQ
Platinol-AQ VHA Plus
Platinum
Abbreviations
CACP
CDDP
Cis-DDP
CPD
CPDC
CPDD
CPPD
DDP
Category
Chemotherapy
Subcategory
Alkylating agent
Platinum analog
NSC Number
119875
Primary Site
Histology
None
Remarks
An alkylating antineoplastic agent. FDA approved uses on bladder, ovarian and testicular cancer; miscellaneous agent.
Coding
This drug should be coded
Name
Alternate Names
Blenoxane
Bleo
Bleo-Cell
Bleo-S
Bleomycin for Injection
Bleomycin sulfate
Oil Bleo
Abbreviations
BLE
BLEO
BLM
Category
Chemotherapy
Subcategory
Antitumor antibiotic
NSC Number
125066
Primary Site
Histology
None
Remarks
FDA approved uses on squamous cell cervical cancer, head & neck cancer, Hodgkin's and non-Hodgkin's lymphoma, nasopharyngeal cancer, carcinoma, and testicular cancer.
Coding
This drug should be coded
Name
Alternate Names
Compound 112531
Eldesine
Eldisine
Lilly 99094
LY-099094
Vincaleukoblastine
Vindesine sulfate
Abbreviations
DAVA
DVA
Category
Chemotherapy
Subcategory
Plant alkyloid
NSC Number
245467
Primary Site
None
Histology
None
Remarks
Vindesine has activity in a wide variety of malignancies including colorectal, lung, breast, and esophageal carcinomas; it also has activity in lymphomas and leukemias, glioma, and melanoma. Neurotoxicity (dose-limiting and cumulative) and cross-resistance with vincristine have limited the usefulness of this agent. Although vindesine in combination with cisplatin is one of the most active regimens for non-small cell lung cancer.
Coding
This drug should be coded